NuPathe Files for IPO


NuPathe Inc., a Conshohocken, Penn.-based drug developer focused on the central nervous system, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol PATH, with Lazard Capital Markets and Leerink Swann serving as co-lead underwriters.

The company reports $11.3 million in 2009 revenue and a $15.6 million net loss.

NuPathe has raised $53 million in VC funding, from firms like Quaker BioVentures, Safeguard Scientifics, Battelle Ventures, Birchmere Ventures, S.R. One Ltd. www.nupathe.com

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.